Core Viewpoint - The supervisory board of Jinhe Biotechnology Co., Ltd. has reviewed and approved the conditions for the release of restricted stock under the 2023 Restricted Stock Incentive Plan, confirming compliance with relevant laws and regulations [1][3]. Summary by Sections Section 1: Review of Incentive Objects - The company meets the conditions for implementing the stock incentive plan as per the Management Measures and relevant regulations, confirming the eligibility of the incentive objects for the second release period and the first reserved grant period [1][2]. - The incentive objects for the current plan do not fall under any disqualifying conditions as outlined in the Management Measures [2]. Section 2: Approval of Release Conditions - The supervisory board has verified that the 70 initial incentive objects and 11 reserved incentive objects meet the conditions for the release of restricted stocks, with a total of 4,326,000 shares for the initial grant and 500,000 shares for the reserved grant approved for release [3]. Section 3: Repurchase and Cancellation of Restricted Stocks - The supervisory board has determined that 43 incentive objects did not fully meet performance targets, leading to the repurchase and cancellation of their unvested restricted stocks, totaling 2,100,000 shares [3][5]. - The repurchase price adjustment and the process for cancellation have been confirmed to comply with relevant regulations, ensuring no harm to the company or shareholders [4][5].

Summary of Key Points Core Viewpoint - The company, Jinhe Biological Technology Co., Ltd., plans to provide a guarantee of up to 100 million yuan for its wholly-owned subsidiary, Inner Mongolia Jinhe Environmental Technology Co., Ltd., to support its financing needs, which exceeds 50% of the company's latest audited net assets [1][2]. Group 1: Guarantee Overview - The board of directors approved the guarantee proposal with a unanimous vote of 9 in favor [1]. - The maximum guarantee amount is set at 10 million yuan, which represents 4.45% of the company's audited net assets for 2024 [1][4]. - The guarantee will be a joint liability guarantee, with the actual amount and duration to be determined in the final guarantee contract [1]. Group 2: Approval Process - The guarantee must be submitted to the shareholders' meeting for special resolution approval and does not involve related transactions or require approval from relevant authorities [2]. - The effective period of the guarantee is 12 months from the date of the shareholders' meeting resolution [2]. Group 3: Financial Situation of the Guaranteed Party - Inner Mongolia Jinhe Environmental Technology Co., Ltd. is a wholly-owned subsidiary with a registered capital of 50 million yuan and an asset-liability ratio of 32.77% [3]. - The subsidiary's recent financial data shows a revenue of approximately 170.12 million yuan for 2024 and a net profit of about 33.14 million yuan [3]. Group 4: Board's Opinion - The board believes that providing this guarantee will meet the subsidiary's operational funding needs and support its healthy and sustainable development [3]. - The company has the ability to control operational and financial risks during the guarantee period, and this action aligns with the company's long-term interests [3]. Group 5: Cumulative Guarantee Situation - As of the announcement date, the total external guarantee balance of the company and its subsidiaries is approximately 513.73 million yuan, which is 22.87% of the company's audited net assets for 2024 [4]. - The new guarantee of 10 million yuan will increase this percentage to 4.45% [4].

关于增加公司 2025 年日常关联交易预计额度的公告 证券代码：002688 证券简称：金河生物 公告编号：2025-060 金河生物科技股份有限公司 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第六届董事会第二十五次会议、第六届监事会第二十次会议及 2025 年 5 月 23 日召开的 2024 年度股东大会审议通过了《关于公司 2025 年度日常关联交易预计 额度的议案》。公司及子公司 2025 年预计发生接受关联人内蒙古金河建筑安装 有限责任公司（以下简称"金河建安"）提供劳务的基本建设项目及基建维修的 关联交易总额为不超过 5,720 万元。子公司及二级子公司 2025 年预计发生接受 关联人北京中业园净化空调工程有限公司（以下简称"北京中业园"）提供劳务 的日常关联交易总额为不超过 517.50 万元。具体内容详见公司于 2025 年 4 月 会第二十五次会议决议公告》《第六届监事会第二十次会议决议公告》和 2025 年 5 月 24 日披露的《2024 年度股东大会决议的公告》。 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误 ...

Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shanghai) Law Firm confirms the completion of the second unlock period for the initial grant of restricted stock and the first unlock period for reserved grants under the 2023 Restricted Stock Incentive Plan of Jinhe Biotechnology Co., Ltd, along with the repurchase and cancellation of certain restricted stocks and adjustments to the repurchase price [1][2][22]. Group 1: Unlock Conditions and Achievements - The second unlock period for the initial grant of restricted stocks is set to be 24 months after the registration completion date, which was completed on July 7, 2023 [13][14]. - The first unlock period for reserved grants is 12 months after the registration completion date, which was completed on December 28, 2023 [14]. - The company has met the performance assessment requirements for the unlock conditions, with a net profit growth rate of 88.29% in 2024, exceeding the required 78% [17][18]. Group 2: Repurchase and Price Adjustment - The company plans to repurchase and cancel a total of 2,100,000 shares of restricted stock due to the departure of certain incentive targets and performance failures [21][22]. - The adjusted repurchase price for the restricted stocks is set at 2.29 yuan per share, following a cash dividend distribution of 1.00 yuan per 10 shares [19][22]. - The repurchase will be funded by the company's own funds, and the repurchase reasons, quantity, price, and funding sources comply with relevant regulations [22].

Core Viewpoint - The company has announced the achievement of conditions for the first unlock period of the reserved stock grant and the second unlock period of the initial stock grant under the 2023 restricted stock incentive plan, allowing 71 incentive recipients to unlock a total of 4,826,000 shares, which represents 0.63% of the company's total share capital [1][2][18]. Summary by Relevant Sections Incentive Plan Overview - The 2023 restricted stock incentive plan initially granted 21,370,000 shares, accounting for approximately 2.74% of the company's total share capital at the time of the plan's announcement [2][11]. - The plan includes a reserved grant of 1,000,000 shares, representing 0.13% of the total share capital [2][11]. Unlock Conditions - A total of 71 incentive recipients are eligible for unlocking, with 70 recipients eligible for the second unlock period of the initial grant (4,326,000 shares) and 11 recipients eligible for the first unlock period of the reserved grant (500,000 shares) [1][2][18]. - The unlocking of shares is subject to the completion of necessary procedures by relevant authorities [1][2]. Performance Assessment - The performance assessment for the first unlock period requires a net profit growth rate of no less than 155% for 2023, based on the 2022 net profit [7][9]. - For the second unlock period, the required growth rate is 78% for 2024, and for the third unlock period, it is 131% for 2025 [9][10]. Compliance and Approval - The board of directors and the supervisory board have reviewed and approved the unlocking conditions, confirming compliance with relevant regulations and the company's articles of association [22][23]. - Legal opinions affirm that the necessary approvals and authorizations have been obtained for the unlocking of shares [24][25].

Mergers and Acquisitions - Hangcha Group's subsidiary plans to increase capital and acquire approximately 99% of Guozhi Robotics [1] - Changhong High-Tech is planning to purchase 100% equity of Guangxi Changke through share issuance and cash payment, which is expected to constitute a major asset reorganization [2] Shareholding Changes - Newray's senior management plans to reduce their holdings by up to 0.3% of the company's shares due to personal financial needs [3] - Zhuoyi Information's employee shareholding platform intends to reduce its holdings by up to 1.88% of the company's shares due to employees' financial needs [4] - Baotong Technology's major shareholders plan to collectively reduce their holdings by up to 2.36% of the company's shares for personal financial reasons [5] Performance Disclosure - Huayou Cobalt expects a year-on-year increase of 56% to 68% in net profit attributable to shareholders for the first half of 2025, driven by integrated operations and rising cobalt prices [6] - Skyworth Digital anticipates a year-on-year decline of 76% to 65% in net profit attributable to shareholders for the first half of 2025 due to a significant drop in sales prices of smart terminal products [7] - Shandong Molong expects a year-on-year decline of 92% to 94% in net profit attributable to shareholders for the first half of 2025, primarily due to the previous year's asset sales [8][9] Investment Matters - Jinhe Biological's wholly-owned subsidiary plans to invest 158 million yuan in a wastewater treatment expansion project to enhance future profitability [10] Risk Matters - Risconda's chairman and a director have been subjected to criminal coercive measures due to allegations of information disclosure violations [11]

证券代码：002688 证券简称：金河生物 公告编号：2025-060 金河生物科技股份有限公司 关于增加公司 2025 年日常关联交易预计额度的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、日常关联交易基本情况 （一）前次日常关联交易预计情况 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第六届董事会第二十五次会议、第六届监事会第二十次会议及 2025 年 5 月 23 日召开的 2024 年度股东大会审议通过了《关于公司 2025 年度日常关联交易预计 额度的议案》。公司及子公司 2025 年预计发生接受关联人内蒙古金河建筑安装 有限责任公司（以下简称"金河建安"）提供劳务的基本建设项目及基建维修的 关联交易总额为不超过 5,720 万元。子公司及二级子公司 2025 年预计发生接受 关联人北京中业园净化空调工程有限公司（以下简称"北京中业园"）提供劳务 的日常关联交易总额为不超过 517.50 万元。具体内容详见公司于 2025 年 4 月 26 日披露的《关于公司 2025 年度日常关联交易 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-059 金河生物科技股份有限公司 关于公司为全资子公司提供担保额度预计的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 特别提示： 1、金河生物科技股份有限公司（以下简称"公司"、"金河生物"）及子 公司累计对外担保金额（包含本次预计新增担保）超过公司最近一期经审计净资 产50%。 2、公司及子公司未对合并报表范围外的公司提供担保。 3、公司及子公司未发生逾期担保、涉及诉讼的担保及因担保被判决败诉而 应承担损失的情况。 一、担保情况概述 公司于2025年7月7日召开第六届董事会第二十七次会议，以9票同意，0票反 对，0票弃权审议通过了《关于公司为全资子公司提供担保额度预计的议案》。 为满足子公司正常生产经营的资金需求，公司拟为全资子公司内蒙古金河环保科 技有限公司（以下简称"金河环保"）在金融机构申请融资时提供担保，担保最 高额度为不超过10,000万元，占公司2024年经审计归属于母公司所有者净资产的 比例为4.45%，担保方式为连带责任保证担保。实际担保金额及担保期限等以最 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-058 金河生物科技股份有限公司 关于全资子公司投资建设污水处理扩容及 水资源再生利用提标扩建工程项目的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、投资项目概述 因金河生物科技股份有限公司（以下简称"公司"）全资子公司内蒙古金河 环保科技有限公司（以下简称"金河环保"）业务发展需要，为进一步提高金河 环保污水处理能力及水资源再生利用提标规模，金河环保拟实施污水处理扩容及 水资源再生利用提标扩建工程项目（以下简称"本项目"）。本项目预计总投资 额为 15,842.38 万元，资金来源为自有资金和自筹资金。 2025 年 7 月 7 日，公司召开第六届董事会第二十七次会议，以 9 票同意，0 票反对，0 票弃权审议通过了《关于全资子公司投资建设污水处理扩容及水资源 再生利用提标扩建工程项目的议案》。本次投资事项在公司董事会审批权限范围 内，无需提交公司股东大会审议。本次投资事项不构成关联交易，不构成《上市 公司重大资产重组管理办法》规定的重大资产重组。本项目目前已取得部分行政 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-061 金河生物科技股份有限公司 关于召开 2025 年第四次临时股东大会通知的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、召开会议的基本情况 1、股东大会届次：2025 年第四次临时股东大会 2、会议召集人：金河生物科技股份有限公司（以下简称"公司"）董事 会 3、会议召开的合法、合规性：公司于 2025 年 7 月 7 日召开了第六届董事 会第二十七次会议，会议决定于 2025 年 7 月 23 日召开公司 2025 年第四次临 时股东大会。本次股东大会的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》等的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 7 月 23 日下午 14:30 （2）网络投票时间：2025 年 7 月 23 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 7 月 23 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳 证券交易 ...